Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR12696728

—

adf59f7f-3b6d-5cd5-83b2-b2c3a9dd4a4f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ADIPOGENESIS+0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • TGF_BETA_SIGNALING+0.500
  • HYPOXIA+0.400
  • MYOGENESIS+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.400
  • UV_RESPONSE_DN+0.400
  • ANGIOGENESIS+0.300
  • APICAL_JUNCTION+0.300
  • HEDGEHOG_SIGNALING+0.300

Top 10 suppressed

  • E2F_TARGETS-0.300
  • SPERMATOGENESIS-0.300
  • G2M_CHECKPOINT-0.200
  • MYC_TARGETS_V1-0.200
  • PANCREAS_BETA_CELLS-0.200
  • PROTEIN_SECRETION-0.200
  • DNA_REPAIR-0.100
  • KRAS_SIGNALING_DN-0.100
  • MTORC1_SIGNALING-0.100
  • MYC_TARGETS_V2-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_3216_T1_RNA
breast-umap@18
—A0.853
2BS_4Y6BCYK5
brain-umap@2
pilocytic astrocytoma—0.825
3TCGA-64-5815-01A-01R-1628-07
lung-landscapes@6
—cohortA10.817
4MBCProject_0381_T2_RNA
breast-umap@18
—A0.814
5BSR_19_0096_S47
breast-umap@18
—A0.812
6JHH6_LIVER
ccle-hcc@v2024.1
HCC—0.810
7TCGA-95-7039-01A-11R-1949-07
lung-landscapes@6
—cohortA10.809
873A8C537-1F73-49FE-84BC-E9CC82D2A63E
brain-umap@2
——0.806
9TCGA-60-2707-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.803
10SRR12696776
melanoma-umap@29
——0.802

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ADIPOGENESIS0.500Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
TGF_BETA_SIGNALING0.500Inavolisib— uncovered
HYPOXIA0.400Idelalisib— uncovered
MYOGENESIS0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
UV_RESPONSE_DN0.400Inavolisib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
HEME_METABOLISM0.300Temsirolimus— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
UV_RESPONSE_UP0.300Idelalisib— uncovered
ANDROGEN_RESPONSE0.200Inavolisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
COAGULATION0.200Binimetinib— uncovered
COMPLEMENT0.200Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.200Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered
FATTY_ACID_METABOLISM0.200Inavolisib— uncovered